TuHURA Biosciences, Inc./NV (HURA): debt financing — TuHURA secures $50M credit facility from largest stockholder affiliate to fund operations into Q1 2028

TuHURA Biosciences, Inc./NV

$50M revolving credit facility from Parkview (affiliate of largest stockholder) at 12% interest, matures April 2031.
Monthly draws capped at greater of $1.7M or monthly budget; expects runway into Q1 2028.
Commitment fee $5M paid in 1.88M shares (subject to stockholder approval) or cash; annual 1.5% facility fee.
Granted low-to-mid single digit royalty on IFx-2.0 sales up to $450M/year; warrants extended to 2031.
Change of control conversion price $2.662/share, requires stockholder approval.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.99

TuHURA Biosciences, Inc./NV incurred revolving credit of $50 million revolving credit facility with Parkview Holdings One LLC at 12% per annum (plus additional 6% during an event of default) maturing April 21, 2031.

Instrument: revolving credit
Principal: $50 million revolving credit facility
Counterparty: Parkview Holdings One LLC
Rate: 12% per annum (plus additional 6% during an event of default)
Maturity: April 21, 2031
Event: incurrence

Exact text from the filing

On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.4

TuHURA Biosciences, Inc./NV issued common stock to Parkview Holdings One LLC for conversion price per share equal to $2.662.

Security: common stock
Purchaser: Parkview Holdings One LLC
Consideration: conversion price per share equal to $2.662

Exact text from the filing

convert all outstanding principal plus accrued and unpaid interest into shares of Company common stock (“Conversion Shares”) at a conversion price per share equal to $2.662

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.7

TuHURA Biosciences, Inc./NV issued 1,878,287 shares of common stock to Parkview Holdings One LLC for commitment fee equal to ten percent (10%) of the total commitment.

Security: common stock
Shares: 1,878,287 shares
Purchaser: Parkview Holdings One LLC
Consideration: commitment fee equal to ten percent (10%) of the total commitment

Exact text from the filing

pay a one-time loan commitment fee equal to ten percent (10%) of the total commitment under the Loan Agreement (resulting in a commitment fee of $5.0 million), which the Company has elected to pay by the issuance of an aggregate of 1,878,287 shares of Company common stock (the “Loan Fee Shares”) to Parkview

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TuHURA Biosciences, Inc./NV entered into Loan Agreement with Parkview Holdings One LLC valued at $50 million (effective 2026-04-21).

Action: entry
Agreement: credit facility
Counterparty: Parkview Holdings One LLC
Value: $50 million
Effective: 2026-04-21

Exact text from the filing

On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement.

View on SEC.gov

26 debt financings filed in the last 30 days. Browse all debt financings →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001193125-26-168395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.